Mark Asset Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$831K Buy
+4,314
New +$465K 0.06% 34
2023
Q4
– Sell
-15,604
Closed -$1.61M – 56
2023
Q3
$1.61M Sell
15,604
-26,471
-63% -$2.95M 0.29% 38
2023
Q2
$5.11M Sell
42,075
-425
-1% -$56.7K 0.83% 31
2023
Q1
$6.53M Sell
42,500
-1,904
-4% -$314K 1.19% 28
2022
Q4
$7.98M Buy
44,404
+34,404
+344% +$5.63M 1.81% 22
2022
Q3
$1.18M Hold
10,000
– – 0.29% 37
2022
Q2
$1.43M Buy
+10,000
New +$1.43M 0.35% 40
2022
Q1
– Sell
-27,264
Closed -$6.92M – 54
2021
Q4
$6.92M Sell
27,264
-23,871
-47% -$6.98M 0.79% 32
2021
Q3
$19.7M Sell
51,135
-4,210
-8% -$1.55M 2.12% 18
2021
Q2
$13M Buy
55,345
+27,714
+100% +$4.95M 1.6% 27
2021
Q1
$3.62M Buy
+27,631
New +$4M 0.54% 40

Other funds holding MRNA

Mark Asset Management's MRNA Position: Q3 2026 in Review

Mark Asset Management opened a new position in Moderna (MRNA) in Q3 2026: 4,314 shares worth $831K. The stake represents 0.06% of the portfolio and ranks #34 among its holdings. This is a return to the name: Mark Asset Management previously reported a position in MRNA as recently as Q3 2023.

Mark Asset Management first reported a position in MRNA in Q1 2021 and has held it in 11 quarters since. The position peaked at $19.7M in Q3 2021. 1,028 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Mark Asset Management held 4,314 shares of Moderna worth $831K as of Q3 2026.
  • Moderna was a new Mark Asset Management position in Q3 2026.
  • Moderna made up 0.06% of Mark Asset Management's portfolio in Q3 2026, its #34 holding.
  • Mark Asset Management first reported a position in Moderna in Q1 2021 and has held it in 11 quarters since.
  • Mark Asset Management's Moderna position peaked at $19.7M in Q3 2021.
  • 1,028 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Mark Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.